Trial Profile
Phase II Trial to Evaluate the Efficacy of Auranofin and Sirolimus in Serous Ovarian Cancer Patients With Recurrent Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Mar 2024
Price :
$35
*
At a glance
- Drugs Auranofin (Primary) ; Sirolimus (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- 14 Mar 2024 Planned End Date changed from 15 Dec 2023 to 30 Jun 2024.
- 11 Jul 2023 Planned End Date changed from 15 Oct 2023 to 15 Dec 2023.
- 24 Apr 2023 Planned End Date changed from 15 Mar 2023 to 15 Oct 2023.